Aletira Therapeutics is a venture (Blackbird)-backed biotech developing next-generation gene therapies enabled by alternative splicing. Our platform uses selective exons, or SELEXONS™, to restrict gene expression to specific target cells, enhancing precision while expanding the range of promoters that can be used to achieve therapeutic levels of expression. This approach is designed to improve safety, durability, and dose flexibility relative to conventional gene therapy strategies.